ATE257332T1 - Vitamin formulierung für kardiovaskuläre gesundheit - Google Patents

Vitamin formulierung für kardiovaskuläre gesundheit

Info

Publication number
ATE257332T1
ATE257332T1 AT00200967T AT00200967T ATE257332T1 AT E257332 T1 ATE257332 T1 AT E257332T1 AT 00200967 T AT00200967 T AT 00200967T AT 00200967 T AT00200967 T AT 00200967T AT E257332 T1 ATE257332 T1 AT E257332T1
Authority
AT
Austria
Prior art keywords
cardiovascular health
vitamin
vitamin formulation
composition
high level
Prior art date
Application number
AT00200967T
Other languages
English (en)
Inventor
Atef Boulos
Jatin Desai
Neil Martin
Robert Stillman
Marion Udwin
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE257332T1 publication Critical patent/ATE257332T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00200967T 1999-03-18 2000-03-16 Vitamin formulierung für kardiovaskuläre gesundheit ATE257332T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27181099A 1999-03-18 1999-03-18
US51251200A 2000-02-24 2000-02-24

Publications (1)

Publication Number Publication Date
ATE257332T1 true ATE257332T1 (de) 2004-01-15

Family

ID=26955120

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00200967T ATE257332T1 (de) 1999-03-18 2000-03-16 Vitamin formulierung für kardiovaskuläre gesundheit

Country Status (7)

Country Link
EP (1) EP1036510B1 (de)
JP (1) JP2000281574A (de)
CN (1) CN1271579A (de)
AT (1) ATE257332T1 (de)
AU (1) AU2232300A (de)
BR (1) BR0001343A (de)
DE (1) DE60007576D1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1216713A1 (de) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Zusammensetzungen von Estrogen-Zyklodextrin Komplexe
FR2821748A1 (fr) * 2001-03-12 2002-09-13 Laurent Schwartz Utilisation d'un principe actif anti-fibrose pour la preparation d'un medicamment destine a la prevention du cancer broncho-pulmonaire
JP4755353B2 (ja) * 2001-04-02 2011-08-24 興和株式会社 ビタミンｂ１製剤
US6436431B1 (en) * 2001-07-02 2002-08-20 Diane Wright Hoffpauer Fortified rice bran food product and method for promoting cardiovascular health
JP4965096B2 (ja) * 2005-08-19 2012-07-04 テバ製薬株式会社 圧縮成型製剤
JP5249568B2 (ja) * 2007-12-06 2013-07-31 旭化成ケミカルズ株式会社 成形用粉末、およびこれを用いた圧縮成形組成物、ならびに成形用粉末の製造方法
CA2742302C (en) * 2008-11-04 2018-01-02 Vymedic, Llc Antiviral supplement formulations
CA2746902C (en) * 2009-01-23 2017-10-03 Wyeth Llc A multivitamin/mineral formulation to combat the effects of environmental stress; improve immunity and improve energy while addressing vitamin and mineral deficiencies without the negative side effects of a mega dose nutritional supplement
PL2389077T3 (pl) * 2009-01-23 2015-11-30 Wyeth Llc Suplementy diety dla ludzi 50+ do polepszania witalności, odporności, zdrowia oczu i kości
EP2545788A1 (de) * 2011-07-13 2013-01-16 Martin Hulliger Diätisches Mehrkomponentensystem
CN106901378A (zh) * 2017-03-10 2017-06-30 深圳奥萨医疗有限公司 一种适用于女性的保健食品

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2858215A (en) * 1956-07-02 1958-10-28 Barnett Lab Inc Process of preparing vitamin oils in particle form
US4603143A (en) * 1983-05-02 1986-07-29 Basf Corporation Free-flowing, high density, fat soluble vitamin powders with improved stability
US4617294A (en) * 1985-04-22 1986-10-14 Ppg Industries, Inc. Animal feed supplement
JPH06501695A (ja) * 1990-10-01 1994-02-24 ブリガム・アンド・ウイメンズ・ホスピタル 主要血管事象を抑制するためのベータ−カロテン及びビタミンｅ療法
JP4494539B2 (ja) * 1997-02-28 2010-06-30 ディーエスエム アイピー アセッツ ビー．ブイ． 流動自由な乾燥粒子

Also Published As

Publication number Publication date
EP1036510A2 (de) 2000-09-20
AU2232300A (en) 2000-09-21
JP2000281574A (ja) 2000-10-10
BR0001343A (pt) 2001-08-14
DE60007576D1 (de) 2004-02-12
CN1271579A (zh) 2000-11-01
EP1036510A3 (de) 2000-11-08
EP1036510B1 (de) 2004-01-07

Similar Documents

Publication Publication Date Title
WO2003059274A3 (en) Vitamin formulation for cardiovascular health
ATE257332T1 (de) Vitamin formulierung für kardiovaskuläre gesundheit
HUP0303621A3 (en) Pharmaceutical compositions containing combinations comprising an antidiarrheal agent and epothilone or an epothilone
EP0960621A3 (de) Pharmazeutische Zusammensetzungen enthaltend sildenafil
EE200100618A (et) Dieet- või farmatseutiline kompositsioon kasutamiseks hüperoksaluuria vältimiseks või raviks
DE60018100D1 (en) Polymorphe form von atorvastatin-calcium
IL128942A0 (en) Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and pharmaceutical compositions containing the same
PL368610A1 (en) Orodispersible tablets containing fexofenadine
AP2001002125A0 (en) Controlled-rease pharmaceutical formulations.
HUP0302991A3 (en) Isoxazoles and their use as inhibitors of erk and pharmaceutical compositions containing the compounds
GB2361186B (en) Formulation for the prevention of cardiovascular disease
NO332857B1 (no) Inhalasjonskapsel samt anvendelse av slike
HUP0300720A3 (en) Serine protease inhibitors, pharmaceutical compositions containing them and their use
NO914924D0 (no) Direkte komrprimerbar pulverblanding samt fremgangsmaate ved fremstilling derav
ES2052802T3 (es) Composiciones farmaceuticas solubles en la boca que contienen acetilcisteina.
IL158691A0 (en) Solid orally-dispersible pharmaceutical formulation
ES2124736T3 (es) Comprimidos con alto contenido de clorhidrato de colestipol.
MXPA03003795A (es) Formulaciones autoemulsionantes de dosis orales de inhibidores de proteasa de tipo piranona.
PL372322A1 (en) Low dose liquid entecavir formulations and use
IL166483A0 (en) Pharmaceutical compositions containing ciclesonideand an antihistamine
IS5763A (is) Samsetning sem inniheldur karnitín og inósitól fosfat gagnleg sem næringafræðilegt bætiefni eða lyf
HUP0102159A3 (en) Pharmaceutical composition for the treatment of rumen acidosis
MXPA00002462A (es) Formulacion de vitamina para la salud cardiovascular.
HUP0203118A3 (en) Beta disubstituted metalloprotease inhibitors, pharmaceutical compositions containing them and their use
AU2001277786A1 (en) Composition containing ginkgo biloba that inhibit angiogenesis and matrix metalloproteinase

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties